According to the agreement, BE will receive the exclusive right to commercialise the vaccine in India and participate in ...

SOLUTION Group Bhd (SGB), through its wholly-owned subsidiary Solution Biologics Sdn Bhd (SOLBIO), has signed an exclusive ...

Jiangsu Recbio Technology Company Limited, a leading Chinese biopharmaceutical company, today announced they have entered into a licensing cooperation agreement, and commenced the technology transfer ...

Biological E will begin large-scale manufacturing of the HPV9 vaccine once the Technology transfer is completed.

Biological E. to produce Recbio's HPV9 vaccine in India, expanding global access to cervical cancer prevention.

Biological E partners with China’s Recbio to produce REC603 a 9-valent HPV vaccine in India The collaboration aims to expand ...

HYDERABAD: Jiangsu Recbio Technology Co. Ltd, a leading Chinese biopharmaceutical firm, has entered into a licensing and ...

The global Human Papillomavirus (HPV) Vaccines market, valued at USD 5.5 billion in 2024, is anticipated to grow to USD 9.7 billion by 2030 at a CAGR of 9.9%. This report offers comprehensive ...